Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB EBITDA Margin
EBITDA as a percentage of revenue.
Core Laboratories N.V.NYSE: CLB
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 4.6%
EBITDA Margin was 4.6% in Q1 FY2026, down 1.9 pp from a year earlier. On a trailing-twelve-month basis it was 13.8%, up 0.4 pp year over year. Over 3 fiscal years it widened by 1.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 11.5% for the fiscal year ending Dec 2026, down from 13.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 4.6%-9.5 pp QoQ
- Last fiscal yearDec 2025
- 13.5%-0.5 pp YoY
- LTMMar 2026
- 13.8%+0.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.9 pp | -7.4 pp | -5.5 pp |
| 1 year | -0.5 pp | -2.0 pp | -1.5 pp |
| 3 years | +1.5 pp | +2.3 pp | +0.8 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 13.5%
- Year-over-year change
- -0.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.5% | -0.5pp |
| FY2024 | 2024-12-31 | 14.0% | +0.2pp |
| FY2023 | 2023-12-31 | 13.8% | +1.8pp |
| FY2022 | 2022-12-31 | 12.0% | -1.6pp |
| FY2021 | 2021-12-31 | 13.6% | — |
EBITDA Margin vs competitors
How CLB compares with its peers on the latest reported figures
- CLB's LTM Mar 2026 EBITDA Margin of 13.8% is the 7th highest of the 10 companies compared; the peer median is 41.4%.
- Its year-over-year change of +0.4 pp is the 3rd highest of 9, against a peer median of -8.7 pp.
- Over three fiscal years its change of +1.5 pp compares with a peer median of +1.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 51.0% | -26.2 pp | -2.5 pp | |
| LTM Mar 2026 | 45.3% | -14.6 pp | -2.5 pp | |
| LTM Mar 2026 | 43.4% | -1.9 pp | +52.6 pp | |
| LTM Mar 2026 | 42.0% | -11.4 pp | -16.3 pp | |
| LTM Mar 2026 | 41.4% | +9.3 pp | +17.3 pp | |
| LTM Mar 2026 | 22.1% | -6.0 pp | +2.2 pp | |
| LTM Mar 2026 | 13.8% | +0.4 pp | +1.5 pp | |
| LTM Mar 2026 | 11.8% | -20.3 pp | +5.3 pp | |
| LTM Mar 2026 | 5.3% | +1.1 pp | +1.6 pp | |
| LTM Mar 2026 | -29990.6% | — | — | |
| Peer median (excluding CLB) | 41.4% | -8.7 pp | +1.9 pp | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.